Comparison of Weekly Treatment of Postmenopausal Osteoporosis with Alendronate<i>Versus</i>Risedronate Over Two Years

Abstract

Patients receiving 70 mg OW alendronate had greater gains in BMD, were more likely to maintain or gain BMD, and had greater reductions in bone turnover markers than patients receiving 35 mg OW risedronate after 24 months, with no differences in upper gastrointestinal tolerability.